SAN FRANCISCO, May 19, 2022 (Newswire.com) - Entitled "Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptinin Combination with Filgrastim in Early Recovery" the study results will be presented during the Latebreaker Session on Saturday, May 21, 2022 at the World Congress on Heart Failure 2022 in Madrid by the Principal Investigator Dirk von Lewinski from the Department of Cardiology of the Medical University of Graz.
Patients included in this trial experienced a severe form of Myocardial Infarction known as STEMI. Soon after the initial intervention to re-establish adequate blood flow to the coronary arteries, patients began a two-week treatment with Recardio's dutogliptin, a small molecule that enables sustained targeting and homing of mobilised stem cells to the site of cardiac injury. By releasing paracrine factors, stem cells have been shown to have significant repair and regenerative effects that improve healing and recovery of cardiac function after the infarction.
Recardio Inc. is a late clinical-stage life science company focusing on therapies for cardiovascular and other diseases. The company is located in San Francisco, California, and is having its operations in USA and Europe. The company's lead drug candidate, dutogliptin, is a DPP-IV inhibitor having demonstrated significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration resulting in healing cardia tissue after an injury.
Recardio is currently initiating its global pivotal Phase 3 clinical program in acute myocardial infarction for market authorization in major markets and will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases.
In addition, other development programs are in preclinical stage.
For more information, visit: http://www.recardio.eu or contact email@example.com
Source: Recardio Inc.